基于专利法与竞争法交叉视角下的制药产业专利常青策略

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (905 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The evergreening of patent in pharmaceutical industry,which refers to different ways to extend original patents,has increasingly drawn attention worldwide.To solve the problem,a key point is whether relying on the reform of patent law or applying competition law.This paper analyzes different attitudes in India,the U.S.,EU and Canada,and finally concludes that given the unique nature of pharmaceutical industry,the patentability criterion should be appropriately applied and competition law should be applied in a manner that differs from the way it is applied to companies in other sectors.

Key words： Evergreening of patent Pharmaceutical industry Patent law Competition law

Received: 18 March 2014

PACS:

D923.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhao Xin
	Liu Xiaohai

Cite this article:

Zhao Xin,Liu Xiaohai. Evergreening of Patent in Pharmaceutical Industry: Crossroad between Patent Law and Competition Law[J]. , 2014, 0(11): 81-85.

URL:

http://www.zgkjlt.org.cn/EN/ OR http://www.zgkjlt.org.cn/EN/Y2014/V0/I11/81

[1]Inderjit B.Evergreening——A Controversial Issue in Pharma Milieu[J].Journal of Intellectual Property Rights,2009,14(2):298-299.
[2]Thomas R.Patent “Evergreening”:Issues in Innovation and Competition[C].Congressional Research Service,2009,1(1):10-11.
[3]Joanna B.Intellectual Property and Health Technologies,Balancing Innovation and the Public Health [M].New York:Springer Science and Business Media,2014.158.
[4]Jonathan D.Debunking the “Evergreening” Patents Myth[N].Harvard Law Record,December 8,2010,Vol.CXXXI,No.3.
[5]Kesselheim A.Extensions of Intellectual Property Rights and Delayed Adoption of Generic Drugs:Effects on Medicaid Spending[J].Health Aff.2006,(25):1637-1647.
[6]GSK Briefings.“Evergreening” [EB/OL].(2007-03-01).http://www.gsk.com/policies/GSK-and-evergreening.pdf
[7]Ivar K.The American Inventors Protection Act:the Independent Inventor's Interest& Consumer Choice in the Market[J].Journal of the Patent and Trademark Office Society,2002,(84):503.
[8]Jeanne F.Patent Disclosure[J].Iowa Law Review,2009,(94):539.
[9]Ravinder G.To Patent or Not to Patent? The Case of Novartis' Cancer Drug Glivec in India.[EB/OL](2014-01-06).http://www.globalizationandhealth.com/content/10/1/3.
[10]黄珮珍.专利法对医药衍生物发明之合理评价——以已知物质衍生物为中心[J].成大法学,2012,(23):76.
[11]Lara J.Stretching the Limits of Intellectual Property Rights:Has the Pharmaceutical Industry Gone Too Far? [J].Idea,2001,(41):227.
[12]Competition D G.Pharmaceutical Sector Inquiry Final Report [R].Brussels:European Commission,2009:5.
[13]Richard W.Competition Law[M].Oxford:Oxford University Press.2008:758-759.
[14]Nicoleta T.Patenting Strategies of the EU Pharmaceutical Industry:Crossroad between Patent Law and Competition Policy.[EB/OL](2011-01-01)——http//ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/communication-en.pdf.
[15]William V.Pharmaceuticals and Competition Law,Regulatory Context,Settlement Agreements,and More.(2009-09-24).http://www.cba.org/cba/cle/PDF/COMP09_Vanveen_paper.pdf.